Venous thromboembolism: Management in general practice

Australian Family Physician

Volumn 38, Issue 1-2, 2009, Pages 36-40

  Chapman, Nicola H ^a   Brighton, Timothy ^a   Harris, Mark F ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENERAL PRACTICE; HUMAN; LUNG EMBOLISM; VEIN THROMBOSIS;

FAMILY PRACTICE; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 60149093234     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study - a population based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006;21:722-7.
2. Access Economics, 2008. The burden of venous thromboembolism in Australia. Report for the Australian and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. Available at www.accesseconomics.com.au.
3. Goldhaber SZ. Pulmonary embolism. Lancet 2004;363:1295-305.
4. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Assoc 1998;279:458-62.
5. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
6. Pengo V, Lensing AW, Prins MH, et al. Thromboembolic Pulmonary hypertension study group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
7. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471-5.
8. Heit JA, O'Fallon M, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002;162:1245-8.
9. Hull RD, Schellong SM, Tapson VF, et al. Late breaking clinical trial: extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. [Abstract #O-S-001]. Presented at the XXIst Congress of the International Society on Thrombosis and Hemostasis: 2007 July 6-12, Geneva, Switzerland.
10. National Working Party on the Management and Prevention of Venous Thrombosis. Diagnosis and treatment of venous thromboembolism. Best practice guidelines for Australia and New Zealand. 1st edn. Health Education and Management International, 2004.
11. National Working Party on the Management and Prevention of Venous Thrombosis. Prevention of venous thrombosis. Best practice guidelines for Australia and New Zealand. 4th edn. Health Education and Management International, 2007.
12. Caplan GA. Hospital in the home: a concept under question. Med J Aust 2006;184:599-600.
13. Geerts WH, Berquist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edn. Chest 2008;133(6 Suppl):381S-453S.
14. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acute ill medical patiens with recent reduced mobility: Methodology for the EXCLAIM study. J Thromb Thombolysis 2006;22:31-8.
15. Kuipers S, Schreijer AJM, Cannegieter SC, Buller HR, Rosendaal FR, Middledorp S. Travel and venous thrombosis: a systematic review. J Intern Med 2007;262:615-34.
16. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101-61.
17. Joint European Society of Cardiology/American College of Cardiology committee. Myocardial Infarction redefined: a consensus document of the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
18. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-94.
19. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. Findings from the International Medical Prevention Registry of Venous thromboembolism. Chest 2007;132:936-45.
20. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemostasis 2007;5:1610-16.
21. Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002;88:592-7.
22. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858-69.
23. Eriksson BI, Lassen MR. PENTasaccharide in Hip-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-42.
24. Ho WK, Hankey GJ, Lee CH, Eikelboom JW. Venous thromboembolism: diagnosis and management of deep venous thrombosis. Med J Aust 2005;182:476-81.
25. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of 6 weeks with 6 months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
26. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30.
27. Ansell J, Hirsch J, Hylek E, Jacobson A, Crowther M, Polaret G. Pharmacology and management of vitamin K antagonists. American College of Chest Physicians evidence-based clinical practice guidelines. 8th edn. Chest 2008;133(6 Suppl):160S-98S.
28. Kearon C, Kahn SR, Agnelli F, Goldnaber S, Raskob GE, Comerota AJ. Antithrombotic therapy of venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines. 8th edn. Chest 2008;133(6 Suppl):454S-545S.
29. Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
30. Claes N, Buntix F, Vijgen J, et al. The Belgian Improvement study on oral anticoagulation therapy: a randomized clinical trial. Eur Heart J 2005;26:2159-65.
31. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:1515-22.
32. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006:367:404-11.
33. National Health and Medical Research Council. Available at www.nhmrc.gov.au/nics/asp/index.asp?page=programs/ programs_article&cid=5263&gid=191.
34. Buller HR, Sohme M, Middledorp S. Treatment of venous thromboembolism. J Thromb Haemost 2005;3:1554-60.
35. Breuil AL, Umland EM. Outpatient management of anticoagulant therapy. Am Fam Physician 2007;75:1031-42.
36. Chong BH, Kidson-Gerber G. Deep vein thrombosis and pulmonary embolism. In: Mathias T, editor. Disease index, 4th edn. MIMS Australia, 2007; in press.
37. Kakkar AJ, Haas S. Venous thromboembolism epidemiology, prevention, diagnosis and treatment. Minutes of the Inaugural 'Thrombosis 2020' European experts meeting held in April 2006. Produced by Thrombosis Research Institute. Available at www.trilondon.ac.uk.